Recombinant Mouse FCRL5/FcRH3 Protein, CF

R&D Systems, part of Bio-Techne | Catalog # 6757-FC

R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
6757-FC-050
Print Quote
Bulk Order
100% Guarantee

Key Product Details

Source

NS0

Accession #

NP_899045

Conjugate

Unconjugated

Applications

Bioactivity

View all FCRL5 Proteins and Enzymes »

Product Specifications

Source

Mouse myeloma cell line, NS0-derived mouse FCRL5/FcRH5 protein
Met1-Ala496 with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.01 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

No results obtained: Gln27 predicted

Predicted Molecular Mass

53.5 kDa

SDS-PAGE

65-80 kDa, reducing conditions

Activity

Measured by its ability to bind mouse IgG with an estimated KD <400 nM.

Formulation, Preparation and Storage

6757-FC
Formulation Lyophilized from a 0.2 μm filtered solution in PBS.
Reconstitution
Reconstitute at 100 μg/mL in PBS.

Reconstitution Buffer Available:
Size / Price
Qty
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: FCRL5

Fc Receptor-Like 5 (FCRL5), also known as FcRH3 (FcRH5 in human), IRTA2, and CD307e, is a 90 ‑ 95 kDa member of the FCRL family of proteins whose amino acid (aa) sequence is reminiscent of that for classical Fc receptors. FCLR molecules are type 1 transmembrane proteins that contain from three to nine immunoglobulin-like domains. They are differentially expressed within the B cell lineage, and can either promote or inhibit B cell proliferation and activation (1, 2, 3). Mature mouse FCRL5 consists of a 470 aa extracellular domain (ECD), a 21 aa transmembrane segment, and a 79 aa cytoplasmic region. The ECD contains five Ig-like domains, while the cytoplasmic region possesses one ITAM-like motif and one immunotyrosine inhibitory motif (ITIM) (1, 3, 4). There are two major alleles for FCLR5 in mouse. The first was just described, and is found in BALB/c plus NZB mouse strains. The second is found in C57BL/6 mice, and differs by eleven scattered aa in the ECD. This creates one additional N-linked glycosylation site, and increases the SDS‑PAGE MW by 5 kDa (3). Alternate splicing of mouse FCRL5 generates at least one additional isoform that lacks the first Ig-like domain (aa 3 ‑ 90 of the mature molecule) (4). Human FCRL5, by contrast, contains up to nine Ig-like domains in a highly variable ECD, and over common regions, mouse and human FCRL5 share 49% aa sequence identity. CRL5 expression is restricted to mature B lineage cells in lymphoid tissues and blood, and is particularly noted to be expressed on T‑independent marginal zone and B1 B cells (3 - 8). Its ligation inhibits signaling through the B cell antigen receptor (9). Epstein-Barr virus transformation of B cells induces the up‑regulation of surface FCRL5 by a direct effect of its EBNA2 protein on FCRL5 gene transcription (10). FCRL5 on B cells functions as a receptor for the orthopoxvirus MHC class I-like protein OMCP (11). And based on the literature and R&D Systems testing, both mouse and human FCRL5 will bind to purified IgG with high affinity (5). In human, the FCRL5 gene maps to the 1q21 chromosomal locus, a common site of rearrangements in B cell malignancies. Notably, the FCRL5 protein is preferentially expressed in cell lines with 1q21 abnormalities, and is up‑regulated on tumor cells in some types of B cell malignancies (5, 7, 12 ‑ 14). In addition, soluble FCRL5 is elevated in the serum of many B cell leukemia patients (13, 15).

References

  1. Davis, R.S. (2007) Annu. Rev. Immunol. 25:525.
  2. Maltais, L.J. et al. (2006) Nat. Immunol. 7:431.
  3. Won, W-J. et al. (2006) J. Immunol. 177:6815.
  4. Davis, R.S. et al. (2004) Int. Immunol. 16:1343.
  5. Hatzivassiliou, G. et al. (2001) Immunity 14:277.
  6. Miller, I. et al. (2002) Blood 99:2662.
  7. Polson, A.G. et al. (2006) Int. Immunol. 18:1363.
  8. Vidal-Laliena, M. et al. (2005) Cell. Immunol. 236:6.
  9. Haga, C.L. et al. (2007) Proc. Natl. Acad. Sci. 104:9770.
  10. Mohan, J. et al. (2006) Blood 107:4433.
  11. Campbell, J.A. et al. (2010) J. Immunol. 185:28.
  12. Ise, T. et al. (2005) Clin. Cancer Res. 11:87.
  13. Ise, T. et al. (2007) Leukemia 21:169.
  14. Kazemi, T. et al. (2009) Cancer Immunol. Immunother. 58:989.
  15. Ise, T. et al. (2006) Clin. Chem. Lab. Med. 44:594.

Long Name

Fc Receptor-like 5

Alternate Names

BXMAS1, CD307e, FcRH5, IFGP5, IRTA2, PRO820

Entrez Gene IDs

83416 (Human); 329693 (Mouse)

Gene Symbol

FCRL5

UniProt

NP_899045

Additional FCRL5 Products

Product Documents for Recombinant Mouse FCRL5/FcRH3 Protein, CF

Product Datasheets

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Download SDS

Product Specific Notices for Recombinant Mouse FCRL5/FcRH3 Protein, CF

For research use only

Privacy and Cookie Policy
Site Map
© Copyright 2024 Bio-Techne. All Rights Reserved.